2.13
+0(+0.00%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.1 |
| Day High | 2.29 |
| Day Low | 2.06 |
| 52-Week High | 3.48 |
| 52-Week Low | 1.92 |
| Volume | 39,701 |
| Average Volume | 90,608 |
| Market Cap | 35.86M |
| PE | -0.48 |
| EPS | -4.44 |
| Moving Average 50 Days | 2.28 |
| Moving Average 200 Days | 2.78 |
| Change | 0 |
If you invested $1000 in OncoCyte Corporation (OCX) since IPO date, it would be worth $13.18 as of February 05, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of OncoCyte Corporation (OCX) shares 5 years ago, it would be worth $40.49 as of February 05, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
GlobeNewswire Inc.
Jan 08, 2025 1:30 PM GMT
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Cal
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
GlobeNewswire Inc.
Jan 06, 2025 9:05 PM GMT
Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA)MolDX confirms eligibility for billing under cu
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
GlobeNewswire Inc.
Dec 09, 2024 9:05 PM GMT
January 13-16, 2025, San Francisco, CAIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer And